Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Federica Palermo
Observed names:
F. Palermo,
Palermo F
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Università di Camerino,
University of Urbino,
Candiolo Cancer Institute,
Fondazione IRCCS Istituto Nazionale dei Tumori
ORCID:
0000-0001-6359-6305
Observed ORCID:
0000-0001-6359-6305
OpenAlex ID:
A5048467789
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022
·
Federica Morano
, Alessandra Raimondi
, et al.
·
Journal of Clinical Oncology
·
146
PDF
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
2019
·
Federica Morano
, Salvatore Corallo
, et al.
·
Journal of Clinical Oncology
·
119
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
2024
·
A. Raimondi
, S. Lonardi
, et al.
·
Annals of Oncology
·
113
PDF
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).
2023
·
Filippo Pietrantonio
, Alessandra Raimondi
, et al.
·
Journal of Clinical Oncology
·
106
PDF
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
2021
·
Alessandra Raimondi
, Federica Palermo
, et al.
·
Cancers
·
57
PDF
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
2024
·
Giovanni Randon
, Sara Lonardi
, et al.
·
The Lancet Oncology
·
32
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2019
·
Filippo Pietrantonio
, Riccardo Lobefaro
, et al.
·
Clinical Cancer Research
·
32
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025
·
P. Ciracì
, M.M. Germani
, et al.
·
Annals of Oncology
·
31
PDF
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
2021
·
Paolo Manca
, Salvatore Corallo
, et al.
·
Clinical Cancer Research
·
28
PDF
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
2020
·
Paolo Manca
, Salvatore Corallo
, et al.
·
European Journal of Cancer
·
27
PDF
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024
·
Monica Niger
, Federico Nichetti
, et al.
·
BMC Cancer
·
25
PDF
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
2023
·
Carlotta Antoniotti
, Daniele Rossini
, et al.
·
Journal of Clinical Oncology
·
21
PDF
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
2023
·
Alessandra Raimondi
, Federico Nichetti
, et al.
·
European Journal of Cancer
·
18
PDF
383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
2021
·
F. Pietrantonio
, F. Morano
, et al.
·
Annals of Oncology
·
18
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
2020
·
Filippo Pietrantonio
, Federica Morano
, et al.
·
Clinical Colorectal Cancer
·
17
PDF
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO.
2025
·
Filippo Ghelardi
, Margherita Ambrosini
, et al.
·
Journal of Clinical Oncology
·
15
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
2025
·
Vincenzo Nasca
, Francesca Bergamo
, et al.
·
BMC Cancer
·
13
PDF
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
2025
·
Chiara Cremolini
, Paolo Ciracì
, et al.
·
Journal of Clinical Oncology
·
9
PDF
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
2023
·
Alessandra Boccaccino
, Daniele Rossini
, et al.
·
European Journal of Cancer
·
8
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.
2024
·
Filippo Pietrantonio
, Giovanni Randon
, et al.
·
Journal of Clinical Oncology
·
7
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
2024
·
Monica Niger
, Federico Nichetti
, et al.
·
BMC Cancer
·
5
Abstract CT230: STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI
2026
·
Alberto Giovanni Leone
, Alessandra Raimondi
, et al.
·
Cancer Research
·
4
Observational studies - The Cinderella of the Italian research system
2023
·
Celeste Cagnazzo
, Marco Basiricò
, et al.
·
Tumori Journal
·
4
PDF
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study
2025
·
Carolina Sciortino
, Federico Nichetti
, et al.
·
Digestive and Liver Disease
·
2
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
2025
·
R. Fazio
, G. Randon
, et al.
·
ESMO Open
·
2
PDF
Show more works
View as search
Works count:
67
Citation count:
867
H-index:
15
I10-index:
17
Year
Topic
Type